Matthew Roberts is currently a Director of Cell and Gene Therapy Analytical Development at GlaxoSmithKline. Matt joined GSK in 2011 as part of the company’s Technical Development Program in a joint role between Research & Development and Global Manufacturing & Supply. After completing the Technical Development Program, Matt has held roles as a team lead and manager within GSK’s Biopharmaceutical Analytical Sciences and Cell and Gene Therapy Analytical Development departments, respectively. In those roles, he led teams responsible for the development, qualification, and technical transfer of assays supporting biopharmaceutical and cell and gene therapy characterization, release, and stability testing. Building on this experience, Matt’s current role also comprises leading matrix teams to support asset progression to launch, where his responsibilities include: providing guidance on and driving the delivery of analytical testing strategies, CMC regulatory writing, authoring scientific guidance, and RTQs. Matt received a BS in Biochemistry from the University of Delaware and a PhD in Molecular Biophysics and Biochemistry from Yale University. His graduate research focused on the expression and purification of integral membrane proteins for structural analysis by two-dimensional electron crystallography. In his spare time, his hobbies include cooking, sports, travel, home improvement projects, and getting to know his newborn son.